2.31%C 7.40 5.37%QQQQ 27.81 2.83%
The Global Business News Leader | Friday, 5 Dec 2008
- EQUITY MARKETS
- BONDS AND RATES
- FOREX
- COMMODITIES
- LANGUAGES
- FUNDS
- RETIREMENT
- TAXES
- INSURANCE
- INVESTING
- LANGUAGES
- MOVIE
- MUSIC
- TV
- CELEBRITIES
- LANGUAGES
ABRAXIS BIOSCIENCE INC.
ABII (NASDAQ)
$ 54.48 
Change: +1.48 +2.72% | Volume: 6,464
Change: +1.48 +2.72% | Volume: 6,464
Sponsored by 
ABRAXIS BIOSCI - Fundamental Profile
Company Information
| Ticker Symbol: | ABII |
|---|---|
| Exchange: | NASD |
| Contact Info: | 11755 Wilshire Boulevard Los Angeles CA 90025 310-883-1300 |
| CEO/President: | |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Abraxis BioScience is a fully integrated biotechnology company dedicated to delivering progressive therapeutics and core technologies that offer patients and medical professionals safer and more effective treatments for cancer and other critical illnesses. The Abraxis portfolio includes the world\'s first and only protein-based nanoparticle chemotherapeutic compound which is based on its proprietary tumor targeting system known as the nab Technology platform. From the discovery and research phase to development and commercialization, Abraxis BioScience is committed to rapidly enriching the company\'s pipeline and accelerating the delivery of breakthrough therapies that will transform the lives of the patients who need them. Abraxis, with headquarters in Los Angeles, California, trades on the Nasdaq Global Market under the symbol `ABII.` |
Share Information
| Shares Outstanding: | 40,050 (000) | Market Value: | 2,123,390 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 14.06% | Number of Inst.Shareholders: | 83.41% |
| Last Quarter Sales: | 93.38 ($Mil.) | Last Quarter Net Income: | -15.06 ($Mil.) |
| Last Quarter EPS: | -0.03 | P/E Ratio: | 0 |
| Most Recent Earnings: | Earnings Per Share: | -2.37 | |
| Most Recent Split: | Annual Dividend Rate: | 0 | |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
Most Popular 
ABII
Companies
IBT
- Ahead of the Bell: St. Jude Medical
- UAW grants concessions, exec warns of depression
- Ahead of the Bell: Bank of America
- Hannaford supermarkets restructures corporate HQ
- Ford says CEO will work for $1 to get gov't loans
- Oil plummets below $44 per barrel on economic news
- Yet another statement that China may set up strategic base metals reserve
- U.S. Stocks Gain on Potential Auto Bailout
- U.S Stocks Mixed on Rising Job Cuts, European Rate Cuts
- U.S. Stocks Fall on Service Industry, Employment Woes
- Big Trouble in Big China
- Toyota Group to start importing rare-earth metals from India, Vietnam
- Body-swap illusion tricks mind in new study
- Small plane crashes east of PR capital
Top Competitors
| AMGEN INC. |  |
+15.20 | 57.47 |
| GILEAD SCIENCES |  |
-6.50 | 46.17 |
| CELGENE CORPORA | |
-16.40 | 52.60 |
| GENENTECH INC | |
+1.90 | 75.40 |
| GENZYME CORPORA | |
-17.60 | 63.56 |
Partners   
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives